Give genotype-guided dual antiplatelet therapy a second CHANCE.
- Published in:
- European Heart Journal, 2022, v. 43, n. 10, p. 938, doi. 10.1093/eurheartj/ehac024
- By:
- Publication type:
- Article
Works matching IS 0195668X AND DT 2022 AND VI 43 AND IP 10
Results: 18
1
2
Personalized antithrombotic treatment of cardiovascular disease: a glimpse into the future based on current knowledge.
- Published in:
- European Heart Journal, 2022, v. 43, n. 10, p. 925, doi. 10.1093/eurheartj/ehac086
- By:
- Publication type:
- Article
3
Time for a paradigm shift? Making the case for tailored selection of antiplatelet therapy.
- Published in:
- 2022
- By:
- Publication type:
- Editorial
4
Heparin use in acute coronary syndromes and cardiovascular interventions: habit or evidence based?
- Published in:
- European Heart Journal, 2022, v. 43, n. 10, p. 1008, doi. 10.1093/eurheartj/ehab896
- By:
- Publication type:
- Article
5
CHADS-P2A2RC score: ready to guide the selection of treatment?
- Published in:
- 2022
- By:
- Publication type:
- Editorial
6
Comparative effects of guided vs. potent P2Y12 inhibitor therapy in acute coronary syndrome: a network meta-analysis of 61 898 patients from 15 randomized trials.
- Published in:
- European Heart Journal, 2022, v. 43, n. 10, p. 959, doi. 10.1093/eurheartj/ehab836
- By:
- Publication type:
- Article
7
Appropriate criteria for the definition of Type 4a MI.
- Published in:
- European Heart Journal, 2022, v. 43, n. 10, p. 1013, doi. 10.1093/eurheartj/ehab808
- By:
- Publication type:
- Article
8
Myocardial infarction after elective percutaneous coronary intervention—which cardiac troponin cut-off to use?
- Published in:
- European Heart Journal, 2022, v. 43, n. 10, p. 1012, doi. 10.1093/eurheartj/ehab805
- By:
- Publication type:
- Article
9
Dual antithrombotic treatment in chronic coronary syndrome: European Society of Cardiology criteria vs. CHADS-P2A2RC score.
- Published in:
- European Heart Journal, 2022, v. 43, n. 10, p. 996, doi. 10.1093/eurheartj/ehab785
- By:
- Publication type:
- Article
10
When the solution becomes the problem: left atrial appendage occlusion device-related thrombus after 5 years.
- Published in:
- 2022
- By:
- Publication type:
- Case Study
11
Thrombosis and fibrinolysis in atherosclerotic cardiovascular disease: it takes two to tango.
- Published in:
- 2022
- By:
- Publication type:
- Editorial
12
Ciraparantag as a potential universal anticoagulant reversal agent.
- Published in:
- 2022
- By:
- Publication type:
- Editorial
13
value of 4D flow MRI in cardiac assessment.
- Published in:
- European Heart Journal, 2022, v. 43, n. 10, p. 930, doi. 10.1093/eurheartj/ehab487
- By:
- Publication type:
- Article
14
Ciraparantag reverses the anticoagulant activity of apixaban and rivaroxaban in healthy elderly subjects.
- Published in:
- European Heart Journal, 2022, v. 43, n. 10, p. 985, doi. 10.1093/eurheartj/ehab637
- By:
- Publication type:
- Article
15
Atherothrombotic factors and atherosclerotic cardiovascular events: the multi-ethnic study of atherosclerosis.
- Published in:
- European Heart Journal, 2022, v. 43, n. 10, p. 971, doi. 10.1093/eurheartj/ehab600
- By:
- Publication type:
- Article
16
Patient perspectives: how a quest for better recognition and care united four women from three different continents.
- Published in:
- European Heart Journal, 2022, v. 43, n. 10, p. 935, doi. 10.1093/eurheartj/ehab556
- By:
- Publication type:
- Article
17
long journey of interleukin-1 in acute and recurrent pericarditis.
- Published in:
- European Heart Journal, 2022, v. 43, n. 10, p. 933, doi. 10.1093/eurheartj/ehab529
- By:
- Publication type:
- Article
18
Towards personalized antithrombotic management with drugs and devices across the cardiovascular spectrum.
- Published in:
- European Heart Journal, 2022, v. 43, n. 10, p. 940, doi. 10.1093/eurheartj/ehab642
- By:
- Publication type:
- Article